Chemomab Therapeutics Announces Expected Appointment of Dale R. Pfost as Chairman of the Board


TEL AVIV, Israel, December 16, 2021 / PRNewswire / – Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapies for fibrotic and inflammatory diseases with high unmet need, today announced that, as planned and announced earlier this year, CEO Dale R. Pfost, PhD will assume the additional role of Chairman, subject to approval by Chemomab shareholders, as required by Israeli law. A shareholder vote is expected to take place in or around February 2022. Stephen squinto, PhD, will step down from his current role as Chairman of the Board of Chemomab and Director of the Company, effective December 19, 2021.

Chemomab logo

“Steve was instrumental in the maturation of Chemomab as a public company, and we thank him for his wise leadership and guidance,” said Dr. Pfost. “This is an exciting time for Chemomab as we advance our Phase 2 clinical programs in sclerosing cholangitis and hepatic fibrosis, while preparing to launch a third Phase 2 trial in systemic sclerosis earlier this year. next.

Dr Squinto said: “The time has come for me to hand over the reins of the management of Chemomab, with Dale fully on board as Managing Director, the planned expansion of the management team well underway and the company making good progress in its three clinical programs. I look forward to reports on their continued progress under the leadership of Dale and the experienced leadership team at Chemomab. “

About Chemomab Therapeutics Ltd.

Chemomab is a clinical-stage biotechnology company focused on the discovery and development of innovative therapies for fibrotic and inflammatory diseases with high unmet need. Based on the unique and central role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab has developed CM-101, a monoclonal antibody designed to bind and block the activity of CCL24. CM-101 has demonstrated the potential to treat several serious and life-threatening fibrotic and inflammatory diseases. It is currently in two phase 2 safety and efficacy trials, one in patients with primary sclerosing cholangitis and the second in patients with hepatic fibrosis, with a third phase 2 trial in systemic sclerosis which is expected to start in early 2022.

For more information on Chemomab, visit

Forward-looking statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act. These forward-looking statements include, among others, statements regarding the clinical development path of CM-101; Chemomab’s future operations and its ability to successfully initiate and complete clinical trials and achieve regulatory milestones; the nature, strategy and purpose of Chemomab; the development and commercial potential and potential benefits of any Chemomab product candidate; and that product candidates have the potential to address the significant unmet needs of patients with severe fibrosis-related diseases and conditions. All statements contained in this communication that are not statements of historical fact can be considered as forward-looking statements. These forward-looking statements are based on Chemomab’s current expectations. Forward-looking statements involve risks and uncertainties. Since these statements deal with future events and are based on Chemomab’s current expectations, they are subject to various risks and uncertainties and the actual results, performance or achievements of Chemomab could differ materially from those described or implied by the statements from this presentation, including: the likelihood that Chemomab shareholders will approve the appointment of Dr. Dale pfost as chairman of the board of directors; the uncertain and time consuming regulatory approval process; risks associated with Chemomab’s ability to properly manage its operating expenses and expenses; Chemomab’s plans to develop and commercialize its product candidates, with a focus on CM-101; the launch schedule for the planned clinical trials of Chemomab; the data availability schedule for Chemomab clinical trials; the timing of any investigational new drug request or new drug request; Chemomab’s plans to research, develop and market its current and future product candidates; the clinical utility, potential benefits and market acceptance of Chemomab’s product candidates; Chemomab’s marketing, marketing and manufacturing capabilities and strategy; Chemomab’s ability to protect its intellectual property position; and the requirement for additional capital to continue advancing these product candidates, which may not be available on favorable terms or at all. Additional risks and uncertainties relating to Chemomab and its business can be found under “Risk Factors” and elsewhere in Chemomab’s files and reports with the SEC. Chemomab expressly disclaims any obligation or commitment to publish any update or revision to any forward-looking statement contained herein to reflect any change in Chemomab’s expectations in this regard or any change in the events, conditions or circumstances upon which such statements are made. are based.


Investor Relations:
Irina Koffler
LifeSci Advisors, LLC
Phone: + 1-917-734-7387
[email protected]

Barbara lindheim
Chemomab Therapeutics
Vice-president of the board
Investor and Public Relations, Strategic Communications
Phone: + 1-917-355-9234
[email protected]



View original content:

SOURCE Chemomab Therapeutics Ltd


Comments are closed.